ALGN Stock Recent News
ALGN LATEST HEADLINES
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Align Technology, Inc. ("Align" or the "Company") (NASDAQ: ALGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Align Technology, Inc. (“Align” or the “Company”) (NASDAQ: ALGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the filing of patent infringement lawsuits against Angelalign Technology, Inc. (“Angel”) (Hong Kong Stock Exchange: 6699.HK), a Shanghai-based manufacturer.
SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the filing of patent infringement lawsuits against Angelalign Technology, Inc. (“Angel”) (Hong Kong Stock Exchange: 6699.HK), a Shanghai-based manufacturer.
LOS ANGELES--(BUSINESS WIRE)---- $INSP--ALGN Investors Have Opportunity to Join Align Technology, Inc. Fraud Investigation with the Schall Law Firm.
ALGN's Q2 results disappointed, with revenue and earnings misses and guidance for sequential declines, prompting major restructuring and cautious sentiment. Long-term positives include digital workflow/AI advancements, iTero ecosystem growth, and emerging market momentum, but clear aligner volume stagnation and macro headwinds persist. Despite a strong balance sheet and share buybacks, ALGN trades at a premium for its growth, and sentiment remains neutral-to-bearish, warranting patience and vigilance.
Align Technology ( ALGN ), maker of the clear "smile straightener" Invisalign, reported Q2 2025 adjusted earnings per share (EPS) of $2.49, up 3.3% from the year-ago level. But the profit figure missed the Zacks Consensus Estimate by 3.1%.
SAN DIEGO--(BUSINESS WIRE)--The investigation focuses on whether Align executives made false or misleading statements or failed to disclose material information to investors.
The market can react in unexpected ways to a company's earnings. Sometimes, despite lackluster performance on one or more metrics, a firm's stock may get a bump upward as investors tease out bits of promising information from a report or earnings call.
Align Technology, Inc. holds dominant market share in clear aligners and related hardware/software, with strong international growth potential despite recent U.S. demand softness. Current revenue and margin pressures are largely macro-driven and cyclical; management is proactively cutting costs and optimizing operations to maintain profitability. The company boasts a robust balance sheet, healthy cash flow, and is trading at historically low valuation multiples, offering an attractive risk-reward profile.